Downloads: 1
397 lines (396 with data), 12.8 kB
T1 Age 10 21 53-year-old T2 Sex 22 26 male T3 Sign_symptom 96 104 bleeding E1 Sign_symptom:T3 T4 Duration 109 114 1 day E2 Duration:T4 T5 Clinical_event 39 43 went E3 Clinical_event:T5 T6 Nonbiological_location 51 59 hospital R1 MODIFY Arg1:T6 Arg2:E3 T7 Severity 84 91 massive T8 Biological_structure 92 95 gum R2 MODIFY Arg1:T8 Arg2:E1 R3 MODIFY Arg1:T7 Arg2:E1 T9 History 145 164 chronic hepatitis C T10 Detailed_description 145 152 chronic T11 Disease_disorder 153 164 hepatitis C E4 Disease_disorder:T11 T12 Medication 166 178 PEG-IFN-α-2a E5 Medication:T12 T13 Dosage 180 186 180 μg R4 MODIFY Arg1:T13 Arg2:E5 T14 Medication 193 202 ribavirin E6 Medication:T14 T15 Dosage 204 215 1200 mg/day R5 MODIFY Arg1:T15 Arg2:E6 T16 Duration 248 268 since March 17, 2014 E7 Duration:T16 T17 History 273 305 denied any autoimmune conditions T18 Diagnostic_procedure 337 353 virological data E8 Diagnostic_procedure:T18 T19 Diagnostic_procedure 368 378 virus load E9 Diagnostic_procedure:T19 R6 SUB_PROCEDURE Arg1:E9 Arg2:E8 T21 Diagnostic_procedure 380 387 HCV RNA E10 Diagnostic_procedure:T21 R8 SUB_PROCEDURE Arg1:E10 Arg2:E9 T22 Lab_value 388 403 2.1 × 106 IU/mL R9 MODIFY Arg1:T22 Arg2:E10 T23 Diagnostic_procedure 410 418 genotype E11 Diagnostic_procedure:T23 R10 SUB_PROCEDURE Arg1:E11 Arg2:E8 #1 AnnotatorNotes E8 Specifically, of Hepatitis C T25 Diagnostic_procedure 487 494 HCV RNA E12 Diagnostic_procedure:T25 T26 Lab_value 496 512 2.12 × 106 IU/mL R12 MODIFY Arg1:T26 Arg2:E12 T27 Clinical_event 2874 2884 discharged E13 Clinical_event:T27 T20 Lab_value 419 421 1b E14 Lab_value:T20 R7 MODIFY Arg1:E14 Arg2:E11 T24 Lab_value 363 367 high E15 Lab_value:T24 R11 BEFORE Arg1:E15 Arg2:E9 T28 Sign_symptom 429 449 virological response E16 Sign_symptom:T28 A1 POLARITY E16 NEG T29 Detailed_description 423 428 Rapid R13 MODIFY Arg1:T29 Arg2:E16 T30 Date 474 485 fourth week E17 Date:T30 T31 Sign_symptom 529 549 virological response E18 Sign_symptom:T31 T32 Detailed_description 523 528 early T33 Detailed_description 515 522 Partial R14 MODIFY Arg1:T32 Arg2:E18 R15 MODIFY Arg1:T33 Arg2:E18 T34 Diagnostic_procedure 551 558 HCV RNA E19 Diagnostic_procedure:T34 T35 Diagnostic_procedure 616 623 HCV RNA E20 Diagnostic_procedure:T35 T36 Lab_value 560 569 103 IU/mL E21 Lab_value:T36 T37 Lab_value 625 634 <15 IU/mL E22 Lab_value:T37 R16 MODIFY Arg1:E22 Arg2:E20 R17 MODIFY Arg1:E21 Arg2:E19 T38 Date 573 580 week 12 E23 Date:T38 T39 Date 638 645 Week 24 E24 Date:T39 T40 Sign_symptom 668 675 fatigue E25 Sign_symptom:T40 T41 Sign_symptom 677 683 anemia E26 Sign_symptom:T41 T42 Sign_symptom 689 708 depression syndrome E27 Sign_symptom:T42 A2 TREND E27 INC A3 TREND E26 INC A4 TREND E25 INC T43 Date 728 737 30th week E28 Date:T43 T44 Date 782 789 Week 36 E29 Date:T44 T45 Medication 769 778 treatment E30 Medication:T45 A5 POLARITY E30 NEG T46 Date 813 829 end-of-treatment E31 Date:T46 T47 Diagnostic_procedure 795 805 viral load E32 Diagnostic_procedure:T47 T48 Lab_value 840 852 undetectable E33 Lab_value:T48 R18 MODIFY Arg1:E33 Arg2:E32 T49 Date 2845 2856 December 15 E34 Date:T49 T50 Sign_symptom 2892 2908 stable condition E35 Sign_symptom:T50 T51 Diagnostic_procedure 2914 2929 platelet counts E36 Diagnostic_procedure:T51 T52 Lab_value 2930 2939 elevating E37 Lab_value:T52 R19 MODIFY Arg1:E37 Arg2:E36 T53 Lab_value 2943 2961 117 × 103 cells/μL E38 Lab_value:T53 R20 MODIFY Arg1:E38 Arg2:E36 T54 Diagnostic_procedure 2984 2999 laboratory data E39 Diagnostic_procedure:T54 T55 Sign_symptom 3034 3052 virologic response E40 Sign_symptom:T55 T56 Detailed_description 3024 3033 sustained R21 MODIFY Arg1:T56 Arg2:E40 T57 Date 3000 3014 after 5 months E41 Date:T57 T58 Diagnostic_procedure 3054 3068 platelet count E42 Diagnostic_procedure:T58 T59 Lab_value 3069 3093 above 150 × 103 cells/μL E43 Lab_value:T59 R22 MODIFY Arg1:E43 Arg2:E42 T60 Diagnostic_procedure 3109 3129 anti-cardiolipin IgG E44 Diagnostic_procedure:T60 T61 Lab_value 3099 3108 decreased E45 Lab_value:T61 R23 MODIFY Arg1:E45 Arg2:E44 T62 Lab_value 3131 3138 30.5GPL E46 Lab_value:T62 R24 MODIFY Arg1:E46 Arg2:E44 T63 Diagnostic_procedure 3144 3165 anti-phospholipid IgG E47 Diagnostic_procedure:T63 T64 Lab_value 3167 3174 73.21 U E48 Lab_value:T64 R25 BEFORE Arg1:E48 Arg2:E47 R26 MODIFY Arg1:E45 Arg2:E47 T65 Diagnostic_procedure 858 872 platelet count E49 Diagnostic_procedure:T65 T66 Date 876 879 EOT E50 Date:T66 T67 Date 831 834 EOT E51 Date:T67 R27 IDENTICAL Arg1:E51 Arg2:E31 T68 Lab_value 884 901 92 × 103 cells/μL E52 Lab_value:T68 R28 MODIFY Arg1:E52 Arg2:E49 T69 Lab_value 906 914 elevated E53 Lab_value:T69 T70 Lab_value 918 936 159 × 103 cells/μL E54 Lab_value:T70 T71 Date 937 949 1 week later E55 Date:T71 R29 MODIFY Arg1:E53 Arg2:E49 R30 MODIFY Arg1:E54 Arg2:E49 T72 Date 951 974 Two weeks following EOT E56 Date:T72 T73 Sign_symptom 1010 1018 bleeding E57 Sign_symptom:T73 T74 Biological_structure 1006 1009 gum R31 MODIFY Arg1:T74 Arg2:E57 T75 Severity 998 1005 massive R32 MODIFY Arg1:T75 Arg2:E57 T76 Sign_symptom 1065 1074 petechiae E58 Sign_symptom:T76 T77 Quantitative_concept 1056 1064 multiple R33 MODIFY Arg1:T77 Arg2:E58 T78 Biological_structure 1082 1093 extremities R34 MODIFY Arg1:T78 Arg2:E58 T79 Diagnostic_procedure 1024 1044 physical examination E59 Diagnostic_procedure:T79 T80 Sign_symptom 1129 1139 hemorrhage E60 Sign_symptom:T80 A6 POLARITY E60 NEG T81 Biological_structure 1115 1128 intracerebral R35 MODIFY Arg1:T81 Arg2:E60 T82 Biological_structure 1141 1157 gastrointestinal T83 Sign_symptom 1158 1166 bleeding E61 Sign_symptom:T83 A7 POLARITY E61 NEG R36 MODIFY Arg1:T82 Arg2:E61 T84 Diagnostic_procedure 1208 1222 platelet count E62 Diagnostic_procedure:T84 T85 Detailed_description 1200 1207 initial R37 MODIFY Arg1:T85 Arg2:E62 T86 Lab_value 1227 1242 4 × 103cells/μL E63 Lab_value:T86 R38 MODIFY Arg1:E63 Arg2:E62 T87 Diagnostic_procedure 1244 1263 Coagulation profile E64 Diagnostic_procedure:T87 T88 Lab_value 1271 1277 normal E65 Lab_value:T88 T89 Diagnostic_procedure 1278 1294 prothrombin time E66 Diagnostic_procedure:T89 R39 MODIFY Arg1:E65 Arg2:E66 R40 SUB_PROCEDURE Arg1:E66 Arg2:E64 T90 Diagnostic_procedure 1296 1333 activated partial thromboplastin time E67 Diagnostic_procedure:T90 T91 Diagnostic_procedure 1335 1345 fibrinogen E68 Diagnostic_procedure:T91 T92 Diagnostic_procedure 1347 1354 d-dimer E69 Diagnostic_procedure:T92 T93 Diagnostic_procedure 1360 1386 fibrin degradation product E70 Diagnostic_procedure:T93 R41 MODIFY Arg1:E65 Arg2:E67 R42 MODIFY Arg1:E65 Arg2:E68 R43 MODIFY Arg1:E65 Arg2:E69 R44 MODIFY Arg1:E65 Arg2:E70 R45 SUB_PROCEDURE Arg1:E67 Arg2:E64 R46 SUB_PROCEDURE Arg1:E68 Arg2:E64 R47 SUB_PROCEDURE Arg1:E69 Arg2:E64 R48 SUB_PROCEDURE Arg1:E70 Arg2:E64 T94 Diagnostic_procedure 1388 1410 Peripheral blood smear E71 Diagnostic_procedure:T94 T95 Sign_symptom 1426 1452 fragmented red blood cells E72 Sign_symptom:T95 A8 POLARITY E72 NEG T96 Sign_symptom 1454 1466 helmet cells E73 Sign_symptom:T96 A9 POLARITY E73 NEG T97 Sign_symptom 1471 1500 abnormal platelet aggregation E74 Sign_symptom:T97 A10 POLARITY E74 NEG T98 Disease_disorder 1525 1551 connective tissue diseases E75 Disease_disorder:T98 A11 POLARITY E75 NEG T99 Disease_disorder 1560 1588 systemic lupus erythematosus E76 Disease_disorder:T99 A12 POLARITY E76 NEG T100 Disease_disorder 1592 1608 cryoglobulinemia E77 Disease_disorder:T100 A13 POLARITY E77 NEG T101 Diagnostic_procedure 1639 1660 anti-nuclear antibody E78 Diagnostic_procedure:T101 T102 Diagnostic_procedure 1665 1677 cryoglobulin E79 Diagnostic_procedure:T102 T103 Lab_value 1630 1638 negative E80 Lab_value:T103 R49 MODIFY Arg1:E80 Arg2:E78 R50 MODIFY Arg1:E80 Arg2:E79 T104 Diagnostic_procedure 1698 1718 anti-cardiolipin IgG E81 Diagnostic_procedure:T104 T105 Lab_value 1689 1697 positive E82 Lab_value:T105 R51 MODIFY Arg1:E82 Arg2:E81 T106 Lab_value 1720 1727 116 GPL E83 Lab_value:T106 R52 MODIFY Arg1:E83 Arg2:E81 T107 Diagnostic_procedure 1755 1776 anti-phospholipid IgG E84 Diagnostic_procedure:T107 T108 Lab_value 1778 1783 165 U E85 Lab_value:T108 R53 MODIFY Arg1:E85 Arg2:E84 T109 Disease_disorder 1806 1832 Anti-phospholipid syndrome E86 Disease_disorder:T109 A14 POLARITY E86 NEG T110 History 1853 1886 no previous thromboembolic events T111 Diagnostic_procedure 1906 1922 Sapporo criteria E87 Diagnostic_procedure:T111 T112 Detailed_description 1901 1905 2006 R54 MODIFY Arg1:T112 Arg2:E87 T113 Diagnostic_procedure 1938 1944 biopsy E88 Diagnostic_procedure:T113 T114 Biological_structure 1926 1937 Bone marrow R55 MODIFY Arg1:T114 Arg2:E88 T115 Sign_symptom 1980 1992 hypocellular E89 Sign_symptom:T115 T116 Diagnostic_procedure 2010 2031 cellular distribution E90 Diagnostic_procedure:T116 T117 Biological_structure 1993 1999 marrow R56 MODIFY Arg1:T117 Arg2:E89 R57 MODIFY Arg1:T117 Arg2:E90 T118 Lab_value 2005 2009 even E91 Lab_value:T118 R58 MODIFY Arg1:E91 Arg2:E90 T119 Disease_disorder 2056 2074 lymphoid neoplasia E92 Disease_disorder:T119 A15 POLARITY E92 NEG T120 Medication 2510 2522 Azathioprine E93 Medication:T120 T121 Medication 2578 2596 Hydroxychloroquine E94 Medication:T121 T122 Dosage 2524 2530 100 mg T123 Dosage 2538 2548 once daily T124 Administration 2532 2536 oral R59 MODIFY Arg1:T122 Arg2:E93 R60 MODIFY Arg1:T123 Arg2:E93 R61 MODIFY Arg1:T124 Arg2:E93 T125 Dosage 2598 2604 400 mg T126 Administration 2606 2610 oral T127 Dosage 2612 2622 once daily R62 MODIFY Arg1:T127 Arg2:E94 R63 MODIFY Arg1:T125 Arg2:E94 R64 MODIFY Arg1:T126 Arg2:E94 T128 Diagnostic_procedure 2660 2688 anti-phospholipid antibodies E95 Diagnostic_procedure:T128 T129 Lab_value 2651 2659 positive E96 Lab_value:T129 R65 MODIFY Arg1:E96 Arg2:E95 T130 Diagnostic_procedure 2690 2704 Platelet count E97 Diagnostic_procedure:T130 T131 Lab_value 2715 2724 increased E98 Lab_value:T131 R66 MODIFY Arg1:E98 Arg2:E97 T132 Lab_value 2728 2745 93 × 103 cells/μL E99 Lab_value:T132 R67 MODIFY Arg1:E99 Arg2:E97 T133 Date 2746 2769 17 days after admission E100 Date:T133 T134 Medication 2774 2792 methylprednisolone E101 Medication:T134 T135 Administration 2808 2812 oral R68 MODIFY Arg1:T135 Arg2:E101 T136 Dosage 2829 2840 tapered off R69 MODIFY Arg1:T136 Arg2:E101 T137 Date 2560 2576 since December 3 E102 Date:T137 T138 Sign_symptom 2497 2508 improvement E103 Sign_symptom:T138 A16 POLARITY E103 NEG T139 Medication 2354 2372 methylprednisolone E104 Medication:T139 T140 Administration 2342 2353 intravenous T141 Dosage 2382 2402 40 mg, 3 times daily R70 MODIFY Arg1:T141 Arg2:E104 R71 MODIFY Arg1:T140 Arg2:E104 T142 Date 2407 2418 November 27 E105 Date:T142 T143 Therapeutic_procedure 2433 2464 platelet transfusion treatments E106 Therapeutic_procedure:T143 T144 Disease_disorder 2289 2320 immune thrombocytopenic purpura E107 Disease_disorder:T144 T145 Therapeutic_procedure 2142 2159 Blood transfusion E108 Therapeutic_procedure:T145 T146 Diagnostic_procedure 2196 2204 response E109 Diagnostic_procedure:T146 T147 Lab_value 2191 2195 poor E110 Lab_value:T147 R72 MODIFY Arg1:E110 Arg2:E109 T148 Diagnostic_procedure 2227 2241 platelet count E111 Diagnostic_procedure:T148 T149 Lab_value 2210 2223 rapid decline E112 Lab_value:T149 R73 MODIFY Arg1:E112 Arg2:E111 T150 Date 2249 2257 next day E113 Date:T150 T151 Medication 2090 2125 drugs that may cause platelet lysis E114 Medication:T151 A17 POLARITY E114 NEG R74 AFTER Arg1:E3 Arg2:E1 * OVERLAP E1 E2 R75 AFTER Arg1:E2 Arg2:E4 * OVERLAP E4 E5 E6 E7 R76 BEFORE Arg1:E7 Arg2:E8 R77 BEFORE Arg1:E8 Arg2:E16 * OVERLAP E16 E17 E12 R78 BEFORE Arg1:E12 Arg2:E18 * OVERLAP E18 E19 E23 R79 BEFORE Arg1:E23 Arg2:E20 * OVERLAP E20 E24 R80 BEFORE Arg1:E24 Arg2:E25 * OVERLAP E25 E26 E27 E28 R81 BEFORE Arg1:E28 Arg2:E30 * OVERLAP E30 E29 R82 BEFORE Arg1:E29 Arg2:E32 * OVERLAP E32 E31 E49 E50 R83 BEFORE Arg1:E50 Arg2:E55 R84 MODIFY Arg1:E55 Arg2:E53 R85 MODIFY Arg1:E55 Arg2:E54 R86 BEFORE Arg1:E55 Arg2:E56 * OVERLAP E56 E57 R87 BEFORE Arg1:E57 Arg2:E59 * OVERLAP E59 E58 E60 E61 E62 E64 E71 E72 E73 E74 E75 E76 E77 E78 E79 E81 E84 E86 E87 E88 E89 E90 E92 E114 E108 R88 BEFORE Arg1:E108 Arg2:E109 * OVERLAP E109 E111 E113 E115 T152 Therapeutic_procedure 2261 2272 transfusion E115 Therapeutic_procedure:T152 R89 BEFORE Arg1:E115 Arg2:E107 R90 BEFORE Arg1:E107 Arg2:E104 * OVERLAP E104 E105 E106 R91 BEFORE Arg1:E106 Arg2:E103 R92 BEFORE Arg1:E103 Arg2:E93 * OVERLAP E93 E102 E94 E95 R93 BEFORE Arg1:E95 Arg2:E97 * OVERLAP E97 E100 E101 R94 BEFORE Arg1:E101 Arg2:E34 * OVERLAP E34 E13 E35 E36 R95 BEFORE Arg1:E36 Arg2:E39 * OVERLAP E39 E41 E40 E42 E44 E47